Stock screenerAll disclosures →
EDGAR →
DCOY
Conviction 0HealthcareScan · Thu, Sep 24, 2026Decoy Therapeutics Inc. (DCOY) closed at $3.11 (-19.22%) on Sep 24, 2026. Price is below its 50-day. RSI(14) 49, -81.7% from its 52-week high, -70.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
DCOY$3.11-19.22%
ResistanceSupportVol 14Vol MA14 9.54M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price3.11
Change-19.22%
Gap-4.68%
Rel volume0.16×
Avg volume6.69M
Avg $ vol21.72M
SMA 202.89
SMA 503.60
SMA 200—
Price vs 50-13.58%
Price vs 200—
MA stack—
50/200 cross—
Supertrendup · 3.05
RSI (14)49
MACD hist0.14
MACD cross—
Stoch %K / %D17 / 22
ADX (14)29
+DI / −DI47 / 17
RSI divergenceBullish
MACD divergenceBullish
ATR %22.95%
ADR %16.24%
52w high17.03
52w low2.56
From 52w high-81.74%
Above 52w low+21.48%
New 52w highNo
SqueezeOn · 7d
Bollinger width37.50%
%B0.70
Donchian pos17.13%
Donchian high7.61
Donchian low2.18
AVWAP (52w high)5.65
vs AVWAP high-44.95%
AVWAP (52w low)4.46
vs AVWAP low-30.34%
OBV trendUp
Chaikin MF (20)-0.92
Today vs 20d0.16×
Avg vol (14d)9.54M
Avg vol (20d)6.69M
Avg $ vol (20d)21.72M
Market cap2.04M
RS Rating—
RS 3m (vs SPY)-51.94%
RS 6m (vs SPY)-74.50%
RS line new highNo
Trend template—
Technical rank34.9
1 week+9.89%
1 month+4.36%
3 months-47.45%
6 months-57.69%
1 year—
YTD-70.36%
P/E-0.16
P/B0.47
P/S—
P/FCF-0.42
EPS-129.10
Div yield—
ROE-289.72%
ROA-139.08%
Debt/Eq—
Current1.83
EV/EBITDA0.50
Gross margin—
Net margin—
Rev growth-100.00%
EPS growth-124.52%
Price target—
Target upside—
Analyst rating—
Institutional0.66%
Ent. value-6.25M
Revenue0
Net income-2.37M
Gross profit—
Free cash flow-4.83M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out531.97K
Employees11
ListedThu, Jan 29, 2015
Free float6.37M
Float %99.8%
Short interest13.15K
Days to cover0.6d
Short volume46.5%
Squeeze score8 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$4.46
Last surprise—
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank34.9 / 100
Group rank—
Status laneNo active setup
Setup direction—
Pattern family
Resistance6.03
Support2.38
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Decoy Therapeutics Raises $3.85 Million in Warrant Inducement DealMinichart · Wed, Sep 23, 2026
- Decoy Therapeutics Inducement Warrants Boost Near-Term Liquiditytipranks.com · Wed, Sep 23, 2026
- Form 8K Decoy Therapeutics Inc For: 23 September By Investing.comInvesting.com UK · Wed, Sep 23, 2026
- Decoy Therapeutics Inc.: Unregistered equity sale (dilution)SEC EDGAR · Wed, Sep 23, 2026
- DCOY Stock Slides After Volatile Spike Draws Day Traderstimothysykes.com · Wed, Sep 23, 2026
- DCOY Stock Whipsaws As Traders Game Biotech VolatilityStocksToTrade · Wed, Sep 23, 2026
- DCOY Stock Whipsaws As Traders Target Biotech Volatilitytimothysykes.com · Wed, Sep 23, 2026
- DCOY Stock Volatility Spikes As Traders Track Key LevelsStocksToTrade · Wed, Sep 23, 2026
- Decoy Therapeutics (DCOY) Surges 21.09% to $3.10, Testing Resistance at $3.26 - VOLD Alertdars.gov.et · Tue, Sep 22, 2026
- Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleasePR Newswire · Tue, Sep 22, 2026
Congress activity
Disclosed STOCK Act trades in DCOY
No recent disclosed trades by Congress in DCOY. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in DCOY
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Burleson Tess Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
Lieber Jonathan I Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
PIERCE FREDERICK II Chief Executive Officer · Common Stock · 2026-08-31 | Grant | 33.45K | — | 2026-08-31 | 2026-09-02 |
HANISH ARNOLD C Director · Common Stock · 2026-08-31 | Grant | 3K | — | 2026-08-31 | 2026-09-02 |
Rosenblum Mark J Chief Financial Officer · Common Stock · 2026-08-31 | Grant | 9.68K | — | 2026-08-31 | 2026-09-02 |
Lammers Paul Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
McVicar William K. Director · Common Stock · 2026-08-31 | Grant | 3K | — | 2026-08-31 | 2026-09-02 |
Hibner Barbara Louise Chief Scientific Officer · Common Stock · 2026-08-31 | Grant | 4.22K | — | 2026-08-31 | 2026-09-02 |
Marschel Peter Klaus Chief Business Officer · Common Stock · 2026-08-31 | Grant | 3.9K | — | 2026-08-31 | 2026-09-02 |
Gauthier Patricia G. Director · Common Stock · 2026-08-31 | Grant | 2K | — | 2026-08-31 | 2026-09-02 |
SEC filings
EDGAR filings in DCOY · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.